[ad_1] Shares of Sangamo Therapeutics Inc. fell 13% on Wednesday after results of a half-life trial of its gene-editing candidate SB-913 for the rare metabolic syndrome of Hunter's Syndrome . Two patients …
Read More »
[ad_1] What happened Actions of Sangamo Therapeutics (Nasdaq: SGMO) have fallen to 24.7% today on large volumes. The company's actions are in response to a somewhat disappointing interim update for its zinc …
Read More »[ad_1] What happened Actions of Sangamo Therapeutics (NASDAQ: SGMO) fell 24.7% today on large volumes. The company's actions are in response to a somewhat disappointing interim update for its zinc finger nuclease …
Read More »
[ad_1] Shares of Sangamo Therapeutics Inc. fell 23% in very active trading on Wednesday morning after the company released the first results of a gene-editing trial for a rare metabolic disorder called …
Read More »